STOCK TITAN
  1. Home
  2. News
  3. BXRX

Baudax Bio Inc - BXRX STOCK NEWS

Welcome to our dedicated news page for Baudax Bio (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baudax Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baudax Bio's position in the market.

News
Baudax Bio Announces Corporate Update
Rhea-AI Summary
Baudax Bio announces plans to initiate clinical development of TI-168 following shareholder approval of corporate actions related to TeraImmune acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13%
Tags
none
-
News
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Rhea-AI Summary
Baudax Bio receives orphan drug designation for TI-168 in Hemophilia A with inhibitors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50.67%
Tags
clinical trial
-
News
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Baudax Bio to participate in H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
News
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
Rhea-AI Summary
Baudax Bio announces dividend of one one-thousandth of a share of newly designated Series C Preferred Stock for each outstanding share of common stock held of record as of Sept. 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
News
Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Rhea-AI Summary
Baudax Bio, Inc. has entered into definitive agreements for the purchase and sale of shares and warrants in a registered direct offering and concurrent private placement. The gross proceeds from the offerings are expected to be approximately $1.9 million. The Company intends to use the net proceeds for pipeline development activities and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
offering
-
News
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Baudax Bio, Inc. announces positive top-line results from Phase 2 BX1000 trial and the acquisition of TeraImmune. The acquisition adds the TI-168 clinical stage asset to their portfolio, a next-generation therapy candidate for Hemophilia A. The company believes this platform has potential for multiple autoimmune disorders. They also highlight the success of their NMB regimen in the trial, which may provide improved control of neuromuscular paralysis for surgical patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
News
Baudax Bio Acquires TeraImmune, Inc.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
125%
Tags
acquisition
-
News
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
clinical trial
-
News
Baudax Bio Announces Date of Reconvened Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
News
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
Rhea-AI Summary
Baudax Bio, Inc. reported positive top-line results from its Phase 2 clinical trial of BX1000, a neuromuscular blocking agent (NMB) for surgical patients. The trial showed that BX1000 was effective at all doses and compared favorably to rocuronium. The company also secured $4 million in gross proceeds from a public offering. Other updates include progress in the development of BX2000 and BX3000, and the asset transfer of ANJESO® to Alkermes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
Stock BXRX logo
Baudax Bio Inc

Nasdaq:BXRX

BXRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BXRX Stock Data

950.33k
43.59M
0.02%
2.68%
3.9%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Malvern

About BXRX

baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.